Whalesbook
THE SEAMLESS LINK
The concluded India-EU Free Trade Agreement is poised to redefine the global pharmaceutical trade dynamics, creating structural competitiveness for India's sector. This agreement is designed to unlock substantial export opportunities for Indian pharmaceutical products in the European Union, a market that has historically presented cost and access barriers for many domestic players.
The EU Gateway Opens
The core of the agreement for the pharmaceutical sector involves the reduction, and in many cases near-elimination, of EU tariffs on Indian formulations, Active Pharmaceutical Ingredients (APIs), and other value-added medicines. Pharmexcil Chairman Namit Joshi highlighted that this near-zero tariff access significantly strengthens the position of Indian products within the EU, a development of particular consequence for India's pharma MSMEs. These smaller enterprises, often possessing strong quality capabilities, have historically struggled with cost and access hurdles in highly regulated markets. The FTA promises smoother market entry, directly enhancing their capacity to scale exports, invest in compliance, and integrate into European supply chains. The agreement aims to establish stable, long-term, and predictable pharmaceutical trade, which could benefit European healthcare systems by ensuring improved affordability, continuity, and security of supply, supported by India's manufacturing base. India's pharmaceutical exports to Europe were estimated at approximately $5.8 billion in FY25, representing roughly 19-21% of its overall pharmaceutical exports. The FTA is expected to further catalyze this growth.
Navigating IP and Price Dynamics
A crucial aspect of the FTA is its balanced approach to intellectual property (IP) rights. The agreement reaffirms TRIPS-aligned protections while simultaneously safeguarding India's established strengths in generics and public health, a balance intended to provide regulatory certainty for manufacturers. While industry bodies like the European Federation of Pharmaceutical Industries and Associations (EFPIA) have stressed the importance of effective Regulatory Data Protection to encourage R&D investment in India, they also assert that the IP provisions will not impede the Indian generic industry's ability to supply essential medicines. For Indian patients, the removal of EU tariffs of up to 11% is anticipated to enhance trade and support greater access to innovative medicines. Saurav Ojha, Co-Founder and Whole-Time Director at Iberia Pharmaceuticals, projects a transformational impact on healthcare access, particularly for high-cost specialty drugs and biologics. While short-term price reductions of 10-20% are expected, the most significant impact is foreseen over the next two to three years, with potential price drops of 40-70% as local manufacturing scales up, biosimilars enter the market, and patent expiries align.
Sectoral Synergies and Outlook
The FTA's impact extends beyond pharmaceuticals. It is projected to significantly enhance India's chemical exports to the EU, potentially doubling them within three years due to phased tariff reductions and enhanced regulatory alignment. For medical devices, tariffs on 90% of European optical, medical, and surgical equipment will drop to zero, improving access to advanced technologies for Indian hospitals and potentially lowering healthcare costs. Industry leaders, including MTaI Chairman Pavan Choudary, state the pact will enable India to expand exports of medical textiles, surgical instruments, and disposables, strengthening its role as a reliable, innovation-driven partner. The agreement is expected to foster deeper technology collaboration, improve regulatory transparency, and reduce friction in trade processes, materially improving the ease of doing business. This multifaceted agreement solidifies India's position not just as the 'pharmacy of the world', but also as a more integrated player in global value chains, poised for enhanced competitiveness and access across critical sectors.